STROMUSC YK11 10mg*100Tablets For Bodybuilding CAS:1370003-76-1

    What is YK-11? Beyond a Simple SARM

    It is a critical misclassification to label YK-11 as a Selective Androgen Receptor Modulator (SARM). While it shares the research-grade status of SARMs, its mechanism of action is fundamentally distinct and far more complex.

    YK-11 is a synthetic steroidal compound derived from a structure similar to DHT (Dihydrotestosterone). Its primary, and most celebrated, proposed mechanism is the inhibition of myostatin, a protein that acts as a "brake" on muscle growth. Myostatin is a negative regulator of skeletal muscle mass; higher levels limit growth, while lower levels permit it. Certain animal breeds, like the Belgian Blue cattle, possess natural myostatin mutations, resulting in their characteristically hyper-muscled "double-muscled" appearance. YK-11 aims to pharmacologically mimic this effect in humans.

    However, its action is dual-faceted. Research suggests YK-11 also functions as a partial agonist of the androgen receptor (AR). Unlike full agonists (like testosterone or potent SARMs like RAD-140), which fully activate the AR, a partial agonist has a lower ceiling of activation. This unique position means it can stimulate anabolic pathways while potentially mitigating some of the androgenic side effects associated with full activation. This combination of myostatin inhibition and partial AR agonism places YK-11 in a category of its own.

    The 10mg dosage form is a common presentation in the research chemical market, offering a standardized unit for experimental protocols. Its features are what set it apart from other performance-enhancing compounds:

    ●Mechanistic Uniqueness: Its primary action as a myostatin inhibitor is its flagship feature. While other compounds may indirectly affect myostatin pathways, YK-11 is specifically touted for its direct antagonism.

    ●Steroidal Backbone with Selective Intent: As a synthetic steroid, it possesses the potent anabolic foundation of its class. However, its partial agonism suggests a designed selectivity, aiming to target muscle and bone tissue with a theoretically reduced impact on organs like the prostate and skin.

    ●Non-Hormonal Growth Pathway: A significant portion of its effects is hypothesized to operate independently of the androgen receptor. By blocking myostatin, it potentially allows for growth even in an environment where AR signaling is already saturated, offering a novel avenue for gains.

    ●Promotion of Cellular Differentiation: Beyond merely enlarging existing muscle cells (hypertrophy), preliminary research indicates YK-11 may stimulate the differentiation of satellite cells into new, functional muscle fibers (hyperplasia). This is a controversial yet profoundly impactful concept, as it suggests the ability to increase the actual number of muscle cells, a feat most AAS cannot claim.

    The application of YK-11 is highly specialized and is not suited for beginners or those seeking mild recomposition.

    ●Mass and Density Phases: Its most common application is during a dedicated bulking phase. Users report gains that are exceptionally dense and hard, devoid of the water retention commonly associated with testosterone or Dianabol. The quality of the muscle accrued is often described as "granite-like."

    ●Breakthrough Plateaus: For advanced athletes who have hit a genetic ceiling in their development, YK-11 offers a mechanistic shock to the system. By unlocking the myostatin brake, it can facilitate growth where other compounds have stagnated.

    ●Strength Potentiation: The significant increases in lean mass and potential effects on bone density (via its AR activity) translate directly to raw strength gains. It is often stacked with other compounds to create a powerful strength-building synergy.

    ●Pre-Competition "Hardening": While not a cutting agent per se, its ability to add dry, lean tissue makes it a potential (albeit risky) tool in the final stages of contest preparation to enhance muscle density and separation without spillover.

    The benefits attributed to YK-11 are dramatic, but must be contextualized within the realm of user reports and preclinical research.

    ●Accelerated Lean Muscle Accretion: The primary benefit is rapid, high-quality muscle growth. Gains of 5-10 pounds of lean tissue in a single cycle are commonly reported, though individual response varies immensely.

    ●Dramatic Strength Increases: Correlated with muscle growth, users experience substantial jumps in their core lifts, often surpassing what is achievable with SARMs alone.

    ●Enhanced Muscle Density and Hardness: The lack of estrogenic activity and water retention means new muscle tissue appears striated and dense from the outset.

    ●Improved Bone Density: As a partial AR agonist, YK-11 has shown an affinity for bone tissue, potentially increasing mineral density and skeletal strength-a benefit often overlooked in bodybuilding.

    ●Muscle "Fullness" and Vascularity: The intracellular hydration and nutrient partitioning effects can lead to a pronounced "pump," increased vascularity, and a perpetually full appearance to the muscles.

    This is where theory meets practice, and caution is paramount.

    ●Dosage: The 10mg tablet is typically split. A common research dosage ranges from 5mg to 10mg per day, divided into two equal administrations (e.g., 5mg AM, 5mg PM) to maintain stable plasma levels. Doses exceeding 10-15mg daily are reported but significantly increase the risk of side effects with diminishing returns.

    ●Cycle Length: Due to its potent and suppressive nature, cycle length should be conservative. A standalone YK-11 cycle, if attempted, should not exceed 6-8 weeks. When stacked with other compounds, 8 weeks is generally the absolute maximum.

    ●Half-Life: The exact half-life of YK-11 in humans is not conclusively established but is estimated to be relatively short, likely in the range of 6-12 hours. This necessitates split dosing to ensure consistent myostatin suppression and AR stimulation throughout the day.

    The term "Post-Therapy Cycle" (PTC), synonymous with Post-Cycle Therapy (PCT), is non-negotiable after a YK-11 cycle. As a steroidal compound that suppresses the hypothalamic-pituitary-testicular axis (HPTA), cessation without a proper PTC will result in a crash, leading to loss of gains, low libido, depression, and fatigue.

    A standard PTC protocol begins 2-3 days after the last YK-11 dose and typically lasts 4-6 weeks. It commonly involves:

    ●A SERM (Selective Estrogen Receptor Modulator) like Nolvadex (Tamoxifen Citrate) at 20-40mg/day, tapering down, or Clomid (Clomiphene Citrate) at 25-50mg/day.

    ●Natural Testosterone Support with supplements containing ingredients like D-Aspartic Acid, Ashwagandha, and Zinc, though these are ancillary to SERMs.

    The goal of PTC is to restart endogenous testosterone production by blocking estrogen receptors in the pituitary, stimulating the release of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH).

    The potency of YK-11 is a double-edged sword, and its side effect profile is a significant cause for concern.

    ●Hypogonadism (Testosterone Suppression): Like all suppressive compounds, it will shut down natural testosterone production. PTC is mandatory, not optional.

    ●Androgenic Effects: Despite being a partial agonist, it can still exhibit androgenic side effects, including accelerated hair loss in predisposed individuals, acne, and increased body hair growth.

    ●Lipid Profile Impact: A consistent report among users is a significant negative impact on cholesterol levels, notably a reduction in HDL (the "good" cholesterol) and an increase in LDL. This necessitates vigilant cardiovascular health monitoring.

    ●Tendon and Ligament Strain: The rapid increase in strength and muscle density can outpace the adaptive capacity of connective tissues. This dramatically increases the risk of strains, tendinitis, and even ruptures. A disciplined approach to training progression is critical.

    ●The "Unknown" Factor: The long-term human toxicity profile of YK-11 is entirely unknown. It is a research chemical with no human trials, meaning all use is experimental and carries inherent, unquantifiable risks.

Brand	STROMUSC
Trade names	YK11; (17α,20E)-17,20-diene-21-carboxylic acid methyl ester
CAS	1370003-76-1
Molar mass	430.541
Formula	C25H34O6
Purity	Above 98%
Apprarance	10mg*100

 

 

Any needs, please contact us

Email: Jasonraws106@gmail.com

WhatsApp: +86-15572565525
Telegram: +86-15871669785

   

                                   

 

    YK-11 10mg represents a fascinating and potent frontier in the realm of performance enhancement. It is not a simple SARM but a complex synthetic steroid with a unique, dual-pronged mechanism targeting both the androgen receptor and the myostatin pathway. Its ability to promote dense, high-quality muscle growth and profound strength gains is supported by a wealth of anecdotal evidence.

    However, this power is counterbalanced by a significant and documented risk profile, including potent suppression, negative cardiovascular effects, and a high risk of injury. Its status as a research chemical means it exists in a legal and safety gray area. For the individual considering its use, a thorough understanding of its mechanisms, a respectful approach to dosing, and an unwavering commitment to Post-Therapy are the absolute bare minimum requirements. It is a tool not for the curious novice, but for the highly informed and experienced individual who has exhausted all conventional avenues and is willing to accept the potential consequences of experimenting with one of the most potent and least-understood compounds in the modern bodybuilding arsenal.

Hot Tags: stromusc yk11 10mg*100tablets for bodybuilding cas:1370003-76-1, China stromusc yk11 10mg*100tablets for bodybuilding cas:1370003-76-1 manufacturers, suppliers, factory, MK2866 Treat Muscular Dystrophy and Osteoporosis, YK11 The strongest SARM for muscle gain, GW501516 Ergogenic performance enhancing, Sarms S 23 selective androgen receptor modulator, AC-262, SR9009 Hormone and Metabolic Regulators